Hims & Hers Health (NYSE:HIMS) Stock Price Up 8.5% – Time to Buy?

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price was up 8.5% during trading on Friday. The stock traded as high as $30.29 and last traded at $30.4550. Approximately 7,747,991 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 23,291,271 shares. The stock had previously closed at $28.06.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Analyst commentary says Hims & Hers’ revenue growth continues to benefit from strong demand for weight-loss products, international expansion and AI-related initiatives. The company may remain attractive to long-term investors despite near-term margin pressure and regulatory uncertainty. Reasons to Retain Hims & Hers Stock in Your Portfolio for Now
• Neutral Sentiment: The company appointed Jon Franklin as chief accounting officer. His technical accounting and controllership experience could strengthen financial reporting infrastructure as Hims & Hers expands, although the management change is not expected to materially alter near-term earnings. Hims & Hers Names Jon Franklin as Chief Accounting Officer
• Negative Sentiment: Several law firms announced or promoted a securities class action against Hims & Hers and certain executives. The case covers investors who bought shares from August 4, 2025, through July 29, 2026, with a November 2, 2026 lead-plaintiff deadline. The litigation stems from allegations related to an FTC complaint and could create legal costs, reputational damage and additional uncertainty, although the allegations have not been proven. Hims & Hers Securities Class Action Alert Bronstein Gewirtz Grossman Class Action Announcement
• Negative Sentiment: Separate commentary raised concerns that Hims & Hers could face a longer period of cash burn. Margin pressure, FDA uncertainty and ongoing investment needs may limit profitability and reduce the valuation investors are willing to pay. Is Hims & Hers Stock Ready for a Longer Cash Burn?

Analyst Ratings Changes

A number of research firms have recently commented on HIMS. Bank of America upped their price objective on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Citigroup lowered their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Morgan Stanley boosted their price objective on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $32.43.

Hims & Hers Health Stock Up 9.7%

The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The firm has a market capitalization of $7.18 billion, a price-to-earnings ratio of -48.92 and a beta of 2.44. The firm has a 50 day moving average price of $29.39 and a two-hundred day moving average price of $28.43.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm’s revenue for the quarter was up 38.2% compared to the same quarter last year. During the same period last year, the company posted $0.17 EPS. On average, equities analysts expect that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Deborah Autor sold 16,773 shares of Hims & Hers Health stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total transaction of $467,128.05. Following the transaction, the insider owned 48,961 shares in the company, valued at approximately $1,363,563.85. The trade was a 25.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 29,277 shares of the company’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $29.95, for a total transaction of $876,846.15. Following the sale, the chief financial officer directly owned 236,527 shares of the company’s stock, valued at approximately $7,083,983.65. This trade represents a 11.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 126,982 shares of company stock worth $3,630,849. 11.76% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of HIMS. Bank of America Corp DE boosted its holdings in Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after acquiring an additional 2,877,550 shares during the period. State of Michigan Retirement System boosted its stake in shares of Hims & Hers Health by 13.7% in the first quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock valued at $48,549,000 after purchasing an additional 280,900 shares during the period. Clear Street Group Inc. grew its holdings in Hims & Hers Health by 23.6% during the 4th quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company’s stock valued at $61,832,000 after purchasing an additional 363,893 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Hims & Hers Health during the 2nd quarter valued at $46,220,000. Finally, Principal Financial Group Inc. increased its stake in Hims & Hers Health by 97.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company’s stock worth $26,620,000 after buying an additional 632,282 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.